Qihua Zhu

China Pharmaceutical University — China

Medicine · Health Sciences

24h-index2.1kcitations106works4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(19), Catalytic C–H Functionalization Methods(14), DNA Repair Mechanisms(8), Catalytic Cross-Coupling Reactions(8), Synthesis and Catalytic Reactions(8)

Publications106 total

Discovery of Novel and Potent Dual PARP1/ERK Inhibitors as a Promising Strategy for Cancer Therapy
Journal of Medicinal Chemistry·2026
Discovery of Novel Orally Bioavailable Polθ Inhibitors with Arylalkyne Scaffolds for Targeting HR-Deficient Cancers
Journal of Medicinal Chemistry·2026
Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer
Journal of Medicinal Chemistry·2026
Discovery of PKMYT1 Inhibitors with a Novel Scaffold for the Treatment of Triple-Negative Breast Cancer
Journal of Medicinal Chemistry·2025
PARPs in liver diseases
npj gut and liver.·2025Open Access
Novel 3-n-butylphthalide derivatives as potent multi-functional anti-IS agents with BBB protective function
Bioorganic Chemistry·2025
Discovery of a novel benzofuran-7-carboxamide-based PARP1/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance
European Journal of Medicinal Chemistry·2025· 1 cited
Characterization of Protein–Ligand Chalcogen Bonds: Insights from Database Survey and Quantum Mechanics Calculations
Journal of Chemical Information and Modeling·2025· 2 cited
Discovery of Orally Potent Small-Molecule CD73 Inhibitor for Cancer Immunotherapy
Journal of Medicinal Chemistry·2025
Discovery and Optimization of Potent and Highly Selective PARP14 Inhibitors for the Treatment of Atopic Dermatitis
Journal of Medicinal Chemistry·2025· 3 cited
Discovery and Optimization of Novel Apo-IDO1 Inhibitors by a Pharmacophore-Based Structural Simplification Strategy
Journal of Medicinal Chemistry·2025· 6 cited
Mild cuprous halide mediated direct C<sup>3</sup> monohalogenation of indoles
Mendeleev Communications·2025Open Access
Discovery of cyanoguanidine derivatives as biased μ-opioid receptor agonists
Bioorganic & Medicinal Chemistry·2024· 2 cited
Design, synthesis, and antitumor activity evaluation of 1,2,3-triazole derivatives as potent PD-1/PD-L1 inhibitors
Bioorganic Chemistry·2024· 5 cited
Discovery of highly potent PARP7 inhibitors for cancer immunotherapy
Bioorganic Chemistry·2024· 6 cited
Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins
European Journal of Medicinal Chemistry·2024· 13 cited
Rational Design of PARP1/c-Met Dual Inhibitors for Overcoming PARP1 Inhibitor Resistance Induced by c-Met Overexpression
Journal of Medicinal Chemistry·2024· 23 citedOpen Access
Design, Synthesis, and Biological Evaluation of <i>Pierardine</i> Derivatives as Novel Brain-Penetrant and <i>In Vivo</i> Potent NMDAR-GluN2B Antagonists for Ischemic Stroke Treatment
Journal of Medicinal Chemistry·2024· 8 citedOpen Access
Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy
Journal of Medicinal Chemistry·2024· 14 citedOpen Access
Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment
European Journal of Medicinal Chemistry·2024· 13 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Yungen Xu(41), Yi Zou(12), Zhaoxing Chu(7), Dezhong Ji(6), Junwei Wang(5), Shihui Huang(5), Shi Shi(4), Guangchao He(4), Kewen Peng(4), Yiran Ge(4), Lei Huang(4), Shiqi Wu(4), Guoqing Gong(4), Hui Shen(4), Tianfang Ma(4), Guangwei He(4), Yizhu Xu(3), Hui Li(3), Ying Bai(3), Yun Yang(3)